The role of local vaginal estrogen treatment in urogenital atrophy

Expert Review of Obstetrics and Gynecology

Volumn 7, Issue 6, 2012, Pages 545-556

  Ulrich, Lian ^a  

^a University of Copenhagen   (Denmark)

Author keywords

local estrogen therapy; topical estrogen; urogenital atrophy; vaginal atrophy; vaginal therapy

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL ACETATE; ESTRIOL; ESTROGEN; PLACEBO;

BACKACHE; CANCER INVASION; CANCER RISK; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; HEADACHE; HOT FLUSH; HUMAN; INFECTION PREVENTION; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NIGHT SWEAT; NONHUMAN; RECURRENT INFECTION; REVIEW; STEADY STATE; TREATMENT DURATION; URINARY TRACT INFECTION; URINE INCONTINENCE; UROGENITAL ATROPHY; UROGENITAL TRACT DISEASE; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA MYCOSIS; VAGINAL PRURITUS;

EID: 84870409440     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/eog.12.64     Document Type: Review

References (59)

1. Huang AJ, Moore EE, Boyko EJ et al. Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors. Menopause 17(1), 121-126 (2010).
2. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 49(4), 292-303 (2004).
3. Stenberg A, Heimer G, Ulmsten U, Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 24(1-2), 31-36 (1996).
4. Barlow DH, Cardozo LD, Francis RM et al. Urogenital ageing and its effect on sexual health in older British women. Br. J. Obstet. Gynaecol. 104(1), 87-91 (1997).
5. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13(6), 509-522 (2010).
6. Versi E, Harvey MA, Cardozo L, Brincat M, Studd JW. Urogenital prolapse and atrophy at menopause: a prevalence study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 12(2), 107-110 (2001).
7. Oskay UY, Beji NK, Yalcin O. A study on urogenital complaints of postmenopausal women aged 50 and over. Acta Obstet. Gynecol. Scand. 84(1), 72-78 (2005).
8. Chen YC, Chen GD, Hu SW, Lin TL, Lin LY. Is the occurrence of storage and voiding dysfunction affected by menopausal transition or associated with the normal aging process? Menopause 10(3), 203-208 (2003).
9. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 14(3), 357-369 (2007).
10. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17(2), 242-255 (2010).
11. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 19(3) 257-271 (2012).
12. Davila GW, Singh A, Karapanagiotou I et al. Are women with urogenital atrophy symptomatic? Am. J. Obstet. Gynecol. 188, 382-388 (2003).
13. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 4, CD001500 (2006).
14. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 12(2), 91-105 (2009).
15. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol. 92(4 Pt 2), 722-727 (1998).
16. Crandall C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J. Womens Health (Larchmt) 11(10), 857-877 (2002).
17. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17(1), 194-203 (2010).
18. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet. Gynecol. 112(5), 1053-1060 (2008).
19. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet. Gynecol. 111(1), 67-76 (2008).
20. Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in postmenopausal women: a critical review. Pain Res. Manag. 13(3), 243-254 (2008).
21. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N. Engl. J. Med. 357(8), 762-774 (2007).
22. Gast MJ, Freedman MA, Vieweg AJ, De Melo NR, Girão MJ, Zinaman MJ; Dyspareunia Study Group. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 16(2), 247-256 (2009).
23. Kingsberg SA. The sexual health benefits of oral low-dose estrogen plus progestogen and vaginal estrogen for postmenopausal women. Menopause 16(2), 224-225 (2009).
24. Labrie F, Cusan L, Gomez JL et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 16(1), 30-36 (2009).
25. Dorr MB, Nelson AL, Mayer PR et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil. Steril. 94(6), 2365-2368 (2010).
26. Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CMA. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst. Rev. 4, CD001405 (2009).
27. Enzelsberger H, Schatten C, Kurz C, Zorzi P. [Treatment of female incontinence by local oestrogen therapy.] Gynaekologische Rundschau 30(Suppl. 1), 235-236 (1990).
28. Enzelsberger H, Kurz C, Schatten C, Huber J. [The effectiveness of intravaginal estriol tablet administration in women with incontinence.] Geburtshilfe Frauenheilkd. 51(10), 834-838 (1991).
29. Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int. J. Gynaecol. Obstet. 82(2), 187-197 (2003).
30. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 329(11), 753-756 (1993).
31. Cardozo L, Lose G, McClish D, Versi E, de Koning Gans H. A systematic review of estrogens for recurrent urinary tract infections: third report of the Hormones and Urogenital Therapy (HUT) Committee. Int. Urogynecol. J. Pelvic Floor Dysfunct. 12(1), 15-20 (2001).
32. Pinggera GM, Feuchtner G, Frauscher F et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. Eur. Urol. 47(2), 243-249 (2005).
33. Bateson DJ, Weisberg E. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears. Menopause 16(4), 765-769 (2009).
34. Felding C, Mikkelsen AL, Clausen HV, Loft A, Larsen LG. Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas 15(3), 241-249 (1992).
35. Weiderpass E, Baron JA, Adami HO et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 353(9167), 1824-1828 (1999).
36. Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 14(1), 23-31 (1991).
37. Weisberg E, Ayton R, Darling G et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 8(1), 83-92 (2005).
38. Dugal R, Hesla K, Sørdal T, Aase KH, Lilleeidet O, Wickstrøm E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet. Gynecol. Scand. 79(4), 293-297 (2000).
39. Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M; VAG-1748 Trial Investigators. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric 13(3), 228-237 (2010).
40. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet. Gynecol. 116(4), 876-883 (2010).
41. Bachmann G, Bouchard C, Hoppe D et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 16(4), 719-727 (2009).
42. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 13(2), 99-107 (1991).
43. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7(3), 156-161 (2000).
44. Casper F, Petri E and the Vaginal Ring Study Group. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Int. Urogynecol. J. 10, 171-176 (1999).
45. Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am. J. Obstet. Gynecol. 201(1), 5-11 (2009).
46. Salminen HS, Sääf ME, Johansson SE, Ringertz H, Strender LE. The effect of transvaginal estradiol on bone in aged women: a randomised controlled trial. Maturitas 57(4), 370-381 (2007).
47. Santen RJ, Demers L, Ohorodnik S et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72(8), 666-671 (2007).
48. Bachmann G. The estradiol vaginal ring-a study of existing clinical data. Maturitas 22(Suppl. 22), S21-S29 (1995).
49. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17β-estradiol vaginal tablets. Climacteric 13(3), 219-227 (2010).
50. Haspels AA, Luisi M, Kicovic PM. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol. Maturitas 3(3-4), 321-327 (1981).
51. Lokkegaard E, Nielsen A, Nielsen L, Lidegaard O. Risk of stroke with postmenopausal hormone therapy: A National Cohort Study. Presented at: The 38th Nordic Congress of Obstetrics and Gynecology. Bergen, Norway, 17-19 June 2012.
52. Cicinelli E, Di Naro E, De Ziegler D et al. Placement of the vaginal 17β-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17β-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. Am. J. Obstet. Gynecol. 189(1), 55-58 (2003).
53. Biglia N, Peano E, Sgandurra P et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol. Endocrinol. 26(6), 404-412 (2010).
54. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer 6(2), 187-195 (1999).
55. Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 2(Suppl. 2), 67-72 (1995).
56. Lars HL, Ole-Erik IO, Carl MR et al.; The HABITS Study Group. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100, 475-482 (2008).
57. von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J. Natl Cancer Inst. 97(7), 533-535 (2005).
58. Alatas E, Yagci B, Oztekin O, Sabir N. Effect of hormone replacement therapy on clitoral artery blood flow in healthy postmenopausal women. J. Sex. Med. 5(10), 2367-2373 (2008).
59. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal Phase 3 study. Menopause 17(3), 480-486 (2010).